Photo by clemono from unsplash
The crystal structure of pirfenidone, [5-methyl-1-phenylpyridin-2(1H)-one], an active pharmaceutical ingredient (API) approved in Europe and Japan for the treatment of idiopathic pulmonary fibrosis (IPF), is reported here for the first… Click to show full abstract
The crystal structure of pirfenidone, [5-methyl-1-phenylpyridin-2(1H)-one], an active pharmaceutical ingredient (API) approved in Europe and Japan for the treatment of idiopathic pulmonary fibrosis (IPF), is reported here for the first time. It was crystallized from toluene by the temperature gradient technique, and crystallizes in the chiral monoclinic space group P21.
Keywords:
active pharmaceutical;
structure pirfenidone;
pirfenidone methyl;
one active;
crystal structure;
pharmaceutical ingredient
Journal Title: Acta Crystallographica Section E: Crystallographic Communications
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Acta Crystallographica Section E: Crystallographic Communications
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!